UBS Group
CSTL icon

UBS Group’s Castle Biosciences CSTL Stock Holding History

UBS Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.13M Buy
89,368
+40,205
+82% +$895K ﹤0.01% 5064
2026
Q1 		$1.21M Sell
49,163
-92,710
-65% -$3.04M ﹤0.01% 5403
2025
Q4 		$5.52M Sell
141,873
-149,489
-51% -$4.82M ﹤0.01% 3922
2025
Q3 		$6.63M Sell
291,362
-72,486
-20% -$1.47M ﹤0.01% 3740
2025
Q2 		$7.43M Buy
363,848
+315,089
+646% +$5.83M ﹤0.01% 3438
2025
Q1 		$976K Sell
48,759
-763,841
-94% -$18.9M ﹤0.01% 5300
2024
Q4 		$21.7M Buy
812,600
+758,466
+1,401% +$23.1M ﹤0.01% 2236
2024
Q3 		$1.54M Buy
54,134
+5,411
+11% +$138K ﹤0.01% 4246
2024
Q2 		$1.06M Sell
48,723
-6,120
-11% -$136K ﹤0.01% 4374
2024
Q1 		$1.21M Buy
54,843
+13,366
+32% +$291K ﹤0.01% 4444
2023
Q4 		$895K Buy
41,477
+23,436
+130% +$412K ﹤0.01% 4597
2023
Q3 		$305K Buy
18,041
+736
+4% +$12.9K ﹤0.01% 5041
2023
Q2 		$237K Buy
17,305
+6,731
+64% +$136K ﹤0.01% 5368
2023
Q1 		$240K Buy
10,574
+89
+0.8% +$2.17K ﹤0.01% 5251
2022
Q4 		$247K Buy
10,485
+3,354
+47% +$77.8K ﹤0.01% 5289
2022
Q3 		$186K Sell
7,131
-9,094
-56% -$255K ﹤0.01% 5154
2022
Q2 		$356K Buy
16,225
+12,376
+322% +$288K ﹤0.01% 4523
2022
Q1 		$173K Sell
3,849
-6,549
-63% -$271K ﹤0.01% 5476
2021
Q4 		$446K Buy
10,398
+9,142
+728% +$478K ﹤0.01% 5065
2021
Q3 		$83K Buy
1,256
+576
+85% +$40.5K ﹤0.01% 5954
2021
Q2 		$50K Sell
680
-8,497
-93% -$561K ﹤0.01% 6428
2021
Q1 		$628K Sell
9,177
-1,966
-18% -$148K ﹤0.01% 4695
2020
Q4 		$748K Buy
11,143
+7,121
+177% +$386K ﹤0.01% 4252
2020
Q3 		$206K Sell
4,022
-2,229
-36% -$99.2K ﹤0.01% 4779
2020
Q2 		$236K Sell
6,251
-432
-6% -$14.8K ﹤0.01% 4680
2020
Q1 		$199K Buy
6,683
+1,490
+29% +$45K ﹤0.01% 4727
2019
Q4 		$178K Buy
5,193
+2,383
+85% +$58.3K ﹤0.01% 5671
2019
Q3 		$51K Buy
+2,810
New +$62.3K ﹤0.01% 6189

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's CSTL Position: Q2 2026 in Review

UBS Group increased its Castle Biosciences (CSTL) stake by 82% in Q2 2026, buying an estimated $895K and bringing the position to 89,368 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #5064.

UBS Group first reported a position in CSTL in Q3 2019 and has held it in 28 quarters since. The position peaked at $21.7M in Q4 2024. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • UBS Group held 89,368 shares of Castle Biosciences worth $2.13M as of Q2 2026.
  • UBS Group bought 40,205 Castle Biosciences shares in Q2 2026, an estimated $895K.
  • Castle Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5064 holding.
  • UBS Group first reported a position in Castle Biosciences in Q3 2019 and has held it in 28 quarters since.
  • UBS Group's Castle Biosciences position peaked at $21.7M in Q4 2024.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.